FIFTH THIRD BANCORP

**Signal Note: Eventide Values-Based Allocation Shift** Eventide's $1.0M entry into Fifth Third Bancorp (a regional bank holding company) signals a notable portfolio diversification away from pure-play biotech into financials—atypical for a fund with explicit biotech allocation mandate. This 21,287-share position may reflect either opportunistic valuation in mid-cap banks or a tactical cash deployment ahead of anticipated biotech M&A activity, though the link to specific pipeline catalysts is unclear without additional context on Eventide's thesis.